These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19835825)

  • 1. Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.
    Olson K; Macias P; Hutton S; Ernst WA; Fujii G; Adler-Moore JP
    Vaccine; 2009 Dec; 28(2):548-60. PubMed ID: 19835825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
    Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
    Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
    Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
    PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
    Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
    PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.
    Morello CS; Levinson MS; Kraynyak KA; Spector DH
    J Virol; 2011 Apr; 85(7):3461-72. PubMed ID: 21270160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
    Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
    J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
    Brans R; Yao F
    BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
    Cortesi R; Ravani L; Rinaldi F; Marconi P; Drechsler M; Manservigi M; Argnani R; Menegatti E; Esposito E; Manservigi R
    Int J Pharm; 2013 Jan; 440(2):229-37. PubMed ID: 22743007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
    J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.
    Freeman EE; White RG; Bakker R; Orroth KK; Weiss HA; Buvé A; Hayes RJ; Glynn JR
    Vaccine; 2009 Feb; 27(6):940-6. PubMed ID: 19071187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.
    Brans R; Akhrameyeva NV; Yao F
    J Invest Dermatol; 2009 Oct; 129(10):2470-9. PubMed ID: 19357711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
    Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
    Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
    Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
    Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.